

Risk of Pneumonia Among Patients With Chronic Kidney Disease in Outpatient and Inpatient Settings

A Nationwide Population-Based Study

Che-Yi Chou, MD, Shu-Ming Wang, MD, Chih-Chia Liang, MD, Chiz-Tzung Chang, MD, Jung-Hsiun Liu, MD, I-Kuan Wang, MD, Lien-Cheng Hsiao, MD, Chih-Hsin Muo, Chiu-Ching Huang, MD, and Ruey-Yun Wang, PhD

Abstract: Patients with chronic kidney disease (CKD) are more at risk for pneumonia than the general population. Patients with pneumonia are usually treated as outpatients. However, previous studies were conducted on the basis of inpatient pneumonia. This method may underestimate the risk of pneumonia in patients with CKD. Therefore, we investigated the risk of pneumonia among CKD patients in both outpatient and inpatient settings.

A total of 15,562 patients with CKD and 62,109 individuals without CKD (matched for age and gender) were taken as subjects in the Longitudinal Health Insurance Database of Taiwan National Insurance from 1996 to 2010. The incidence density rates of inpatient and outpatient pneumonia were calculated. The risk factors associated with pneumonia were analyzed using Cox proportional hazard models with adjustments for confounders.

The incidence density rate of pneumonia was 65.6 per 1000 person-years in patients with CKD and 28.4 per 1000 person-years in individuals without CKD. The incidence density rate of inpatient pneumonia was 43.3 per 1000 person-years in patients with CKD and 16.6 per 1000 person-years in individuals without CKD. CKD was associated with increased risk of pneumonia (adjusted hazard ratio [aHR], 1.97; 95% confidence interval [CI], 1.89–2.05; $P < 0.001$), outpatient pneumonia (aHR, 1.40; 95% CI, 1.31–1.49), and inpatient pneumonia (aHR, 2.17; 95% CI, 2.07–2.29, $P < 0.001$). Patients' comorbidities, including diabetes, cardiovascular disease (CVD), asthma, and chronic

obstructive pulmonary disease (COPD), were independently associated with increased risk of pneumonia.

CKD is associated with the increased risk of both outpatient and inpatient pneumonia. This association is independent of comorbid diabetes, CVD, asthma, and COPD.

(*Medicine* 93(27):e174)

Abbreviations: BNHI = Bureau of National Health Insurance, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, CVD = cardiovascular disease, LHID = Longitudinal Health Insurance Database, NHI = National Health Insurance, NHRI = National Health Research Institute.

INTRODUCTION

Pneumonia is one of the most common sources of infectious morbidities in patients with chronic kidney disease (CKD). Pneumonia in patients with CKD is associated with increased hospitalization, cardiovascular events,^{1,2} and mortality.^{3,4} The pneumonia-related mortality rate of patients with CKD is 14 to 16-fold higher than that of the general population.⁴ The risk of inpatient pneumonia and mortality within 30 days is increased with the decline of renal function in patients with CKD.⁵ However, all previous studies were based on the incidence of inpatient pneumonia. This condition may underestimate the risk of pneumonia because most treatments for pneumonia are provided in outpatient settings. This study thus aims to determine the incidence of both inpatient and outpatient pneumonia in patients with CKD using the National Health Insurance (NHI) data of Taiwan.

MATERIALS AND METHODS

This work is a retrospective cohort study using an encrypted database from the Bureau of National Health Insurance (BNHI). The Institutional Review Board of China Medical waived the need for informed consent. The Longitudinal Health Insurance Database (LHID) of the Taiwan National Health Research Institute (NHRI) was released by BNHI. LHID included all medical records from 1996 to 2010. From these records, one million people were randomly selected. No significant differences were found in the sex and age distributions between LHID and all individuals in the NHRI. The International Classification of Disease Revision, Ninth Clinical Modification (ICD-9-CM) was used for the diagnosis codes. A 1:4 study design was used because an increase in controls did not increase statistical efficiency.⁶

Editor: Wenyu Lin.

Received: June 24, 2014; revised: September 9, 2014; accepted: September 13, 2014.

From the Division of Nephrology and Kidney Institute (C-YC, S-MW, C-CL, C-TC, J-HL, I-KW, C-CH), Department of Internal Medicine; College of Medicine (C-YC, S-MW, C-CL, C-TC, J-HL, I-KW, L-CH, C-HM, C-CH); Division of Cardiology (L-CH), Department of Internal Medicine; Management Office for Health Data (C-HM), and Department of Public Health (R-YW), China Medical University and Hospital, Taichung, Taiwan.

Correspondence: Ruey-Yun Wang, PhD, Department of Public Health, College of Public Health, China Medical University, No. 91 Hsueh Shih Road, Taichung City 404, Taiwan (e-mail: rywang0812@gmail.com).

This study was supported in part by the Executive Yuan National Science Council (Grant number NSC 98-2621-M-039-001), the Clinical Trial and Research Center of Excellence of the Department of Health (Grant number DOH101-TD-B-111-004), the Taiwan Department of Health Cancer Research Center of Excellence (Grant number DOH101-TD-C-111-005), and the China Medical University Hospital (Grant number IMS1). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The authors have no conflicts of interest to disclose.

Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ISSN: 0025-7974

DOI: 10.1097/MD.0000000000000174




FIGURE 1. Flowchart of the study design. CKD = chronic kidney disease, LHID = Longitudinal Health Insurance Database, NHI = National Health Insurance.

Study Sample

Patients with CKD were defined as patients with ICD-9-CM code 585 from LHID who are not in the catastrophic illness patient database. The patients included in this database are those with CKD stages 3 to 5 without renal replacement therapy, including hemodialysis, peritoneal dialysis, and kidney transplantation (Figure 1).⁷ A total of 15,562 patients with CKD and 62,109 patients without CKD (matched for age and sex) were included. Pneumonia was identified using ICD-9-CM codes 481, 482, 485, and 486. Pneumonia-related hospitalization was also recorded. The first episode of pneumonia was recorded for patients who developed more than 1 episode. Patients with pneumonia before CKD diagnosis were excluded because we focused on the primary risk of pneumonia. Time was calculated from the index date of CKD to the date of pneumonia. Comorbidities, including diabetes (ICD-9-CM code 250), hypertension

(401–405), cardiovascular disease (CVD) (410–414), asthma (493), and chronic obstructive pulmonary disease (COPD) (491, 492, 494, and 496) were defined as those that have >3 medical visits.

Statistical Analysis

The distribution of sex, age, and comorbidities for patients with CKD and for control individuals was analyzed using χ^2 test for categorical variables or *t* test for continuous variables. The incidence density was defined as the number of pneumonia cases divided by the total follow-up person-years (expressed as per 1000 person-years). The adjusted hazard ratio (aHR) and the 95% confidence intervals (CIs) of pneumonia risk factors were analyzed using Cox proportional hazard regression models with adjustment for sex, age, hypertension, diabetes, CVD, asthma, and COPD. The statistical significance level was set at a 2-tailed probability value <0.05. All analyses were performed using SAS software version 9.1 (SAS Institute, Cary, NC).

RESULTS

The incidence density rate of pneumonia was 65.6 per 1000 person-years in patients with CKD and 28.4 per 1000 person-years in patients without CKD (Table 1). The incidence density rate was used because the follow-up of patients without CKD was longer than that for patients with CKD. The incidence density rate of inpatient pneumonia was 43.3 per 1000 person-years in patients with CKD and 16.6 per 1000 person-years in patients without CKD. Patients with CKD had a higher rate of diabetes ($P < 0.001$), hypertension ($P < 0.001$), CVD ($P < 0.001$), asthma ($P < 0.001$), and COPD ($P < 0.001$) than patients without CKD. Patients who developed pneumonia were older than those without pneumonia and were also more likely to have CKD, diabetes, hypertension, CVD, asthma, and COPD (Table 2). Of 5536 patients with outpatient pneumonia, 1375 (24.8%) had CKD. Of 7240 patients with inpatient pneumonia, 2661 (36.8%) had CKD. The patients with inpatient pneumonia were older than patients with outpatient pneumonia. Patients

TABLE 1. Demographic Data of Patients With and Without CKD

Clinical Characteristics	Non-CKD n = 62,109		CKD n = 15,562		P Value
Pneumonia (per 1000 person-years)	8740	28.4	4036	65.6	<0.001
Inpatients (per 1000 person-years)	5125	16.6	2661	43.3	<0.001
Follow-up, y	5.0	(0.1–11)	4.0	(0.1–11)	<0.001
Male (n), %	35950	57.9	9011	57.9	0.96
Age (n), %					
<45	7964	12.8	1991	12.8	>0.99
45–54	8900	14.3	2225	14.3	
55–64	11,700	18.8	2925	18.8	
65–74	16,464	26.5	4116	26.5	
≥75	17,081	27.5	4305	27.7	
Mean (SD)	63.3	(16.0)	64.0	(16.0)	
Comorbidity (n), %					
Diabetes	9428	15.2	5653	36.3	<0.001
Hypertension	28,256	45.5	11614	74.6	<0.001
CVD	21,091	34.0	8771	56.4	<0.001
Asthma	4281	6.9	1676	10.8	<0.001
COPD	9305	15.0	3787	24.3	<0.001

COPD = chronic obstructive pulmonary disease, CVD = cardiovascular disease, SD = standard deviation.

TABLE 2. Characteristics of Patients With and Without Pneumonia

Clinical Characteristics	Pneumonia (–) n = 64,895		Pneumonia (Outpatient) n = 5536		Pneumonia (Inpatient) n = 7240	
	n	%	n	%	n	%
CKD (n), %	11,526	17.8	1375	24.8*	2661	36.8* [†]
Male (n), %	37,126	57.2	3299	59.6*	4536	62.7* [†]
Age, y; (n), %						
<45	9311	14.4	453	8.2*	191	2.6* [†]
45–54	10,261	15.8	508	9.2*	356	4.9* [†]
55–64	12,952	20.0	880	15.9*	793	11.0* [†]
65–74	16,839	26.0	1671	30.2*	2070	28.6* [†]
≥75	15,532	23.9	2024	36.7*	3830	52.9* [†]
Comorbidity (n), %						
Diabetes	11,560	17.8	1260	22.8*	2261	31.2* [†]
Hypertension	31,142	48.0	3414	61.7*	5314	73.4* [†]
CVD	22,692	35.0	2800	50.6*	4370	60.4* [†]
Asthma	4097	6.3	886	16.0*	974	13.5* [†]
COPD	8900	13.7	1800	32.5*	2392	33.0*

CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, CVD = cardiovascular disease.

* $P < 0.05$ in χ^2 test compared to patients without pneumonia.

[†] $P < 0.05$ in χ^2 test compared to patients without outpatient pneumonia.

with inpatient pneumonia were more likely to have diabetes, hypertension, and CVD than patients with outpatient pneumonia. The percentage of patients with asthma was lower in patients with inpatient pneumonia than in patients with outpatient pneumonia. The prevalence of patients with COPD was not significantly different between patients with inpatient pneumonia and those with outpatient pneumonia.

CKD, age, male gender, hypertension, diabetes, CVD, asthma, and COPD were associated with increased risk of pneumonia (Table 3). The aHR values of CKD for any type of pneumonia were 1.97 (95% CI, 1.89–2.05, $P < 0.001$) and 1.40 (95% CI, 1.31–1.49) for outpatient pneumonia and 2.17 (95% CI, 2.07–2.29) for inpatient pneumonia. Male gender (aHR, 1.13; 95% CI, 1.07–1.19), comorbid diabetes (aHR, 1.12; 95% CI, 1.05–1.19), comorbid CVD (aHR, 1.11; 95% CI, 1.04–1.20), comorbid asthma (aHR, 1.66; 95% CI, 1.56–1.79), and comorbid COPD (aHR, 1.89; 95% CI, 1.77–2.02) were independently associated with the increased pneumonia risk of outpatients. The comorbid hypertension was not associated with the increased pneumonia risk of outpatients but was

associated with the increased pneumonia risk of inpatients (aHR, 1.10; 95% CI, 1.04–1.16).

DISCUSSIONS

CKD is associated with the increased risk of both outpatient and inpatient pneumonia. The risk of pneumonia was 1.97-fold higher in patients with CKD, 1.4-fold higher for outpatient pneumonia, and 2.17-fold higher for inpatient pneumonia compared with patients without CKD (Table 3). Patients with CKD have not only an increased risk of pneumonia but also an increased severity of pneumonia (indicated by hospitalization) compared with patients without CKD. The risk of overall pneumonia was higher in patients with CKD than in patients with other comorbidities (COPD, asthma, and diabetes). The risk of inpatient pneumonia was also the highest in patients with CKD. These results suggested that CKD might be an independently important contributor to the increased risk of pneumonia. The incidence of pneumonia in this study was higher than that reported in the previous studies^{1,2,5,8–11} because outpatient

TABLE 3. Hazard Ratio of Pneumonia Risk Factors

Risk Factors	Pneumonia (Overall) aHR (95% CI)	Pneumonia (Outpatient) aHR (95% CI)	Pneumonia (Inpatient) aHR (95% CI)
CKD	1.97 (1.89–2.05)	1.40 (1.31–1.49)	2.17 (2.07–2.29)
Age (every 10 additional years)	1.05 (1.05–1.05)	1.02 (1.02–1.03)	1.07 (1.07–1.07)
Male	1.24 (1.20–1.29)	1.13 (1.07–1.19)	1.37 (1.31–1.44)
Hypertension	1.09 (1.04–1.15)	1.03 (0.96–1.11)	1.10 (1.04–1.16)
Diabetes	1.29 (1.24–1.34)	1.12 (1.05–1.19)	1.22 (1.14–1.30)
CVD	1.08 (1.07–1.14)	1.11 (1.04–1.20)	1.10 (1.04–1.16)
Asthma	1.39 (1.32–1.46)	1.66 (1.53–1.79)	1.20 (1.12–1.28)
COPD	1.60 (1.54–1.67)	1.89 (1.77–2.02)	1.41 (1.34–1.49)

aHR = adjusted hazard ratio (adjusted for age, sex, diabetes, hypertension, CVD, asthma, and COPD), CI = confidence interval, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, CVD = cardiovascular disease.

pneumonia was considered in the present work. The increased infection risk in patients with CKD can be explained by uremia-related impairment in monocyte,¹² neutrophil phagocytosis,¹³ T lymphocytes,¹⁴ B lymphocytes,¹⁵ and increased cytokines.¹⁶ The increased risk of inpatient pneumonia in patients with CKD may be related to the comorbidity of patients with CKD because comorbidities are associated with the severity of pneumonia.^{17,18}

The major strength of this study was the sample population size derived from the NHI data of Taiwan. The percentage of inpatient pneumonia was 58.6% in patients without CKD who developed pneumonia and 65.9% in patients with CKD who developed pneumonia. The high hospitalization rate of pneumonia can be attributed to 2 reasons. First, the hospitalization costs in Taiwan are low. Second, most of the hospitalization cost is covered by health insurance, and patients only need to pay 10% of the cost. The high rate of diabetes, hypertension, CVD,^{3,19,20} asthma, and COPD^{21,22} in patients with CKD was consistent with the findings of the previous studies.^{21,22}

The limitations of this study are as follows. First, we could not determine the exact stage of CKD on the basis of the ICD-9-CM code 585. This condition may result in the nondifferential misclassification of CKD definition. Patients with CKD stages 1 and 2 and some patients with CKD stage 3 may be included in either patients with CKD or patients without CKD. This nondifferential misclassification may underestimate the contribution of CKD to the risk of pneumonia in the present analyses. Second, we were unable to identify CKD stages 3 to 5 exactly, and we failed to demonstrate the association of increased pneumonia risk with the worsening of CKD stages. Third, pneumonia severity index variables, such as mental status, vital signs, and laboratory data, were unavailable in LHID. Fourth, the pneumonia pathogen was associated with the severity of pneumonia²³ but was not recorded in LHID. We failed to determine whether any specific pathogen was related to the pneumonia in patients with CKD.

In conclusion, patients with CKD have an increased risk for inpatient and outpatient pneumonia, especially pneumonia that requires hospitalization. The increased risk of pneumonia in patients with CKD is independent of their comorbidity.

ACKNOWLEDGMENT

The authors would like to thank the National Health Research Institute, Taiwan, for providing the data on insurance claims.

REFERENCES

- Guo H, Liu J, Collins AJ, et al. Pneumonia in incident dialysis patients—the United States Renal Data System. *Nephrol Dial Transplant*. 2008;23:680–686.
- Viasus D, Garcia-Vidal C, Cruzado JM, et al. Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. *Nephrol Dial Transplant*. 2011;26:2899–2906.
- Collins AJ, Foley RN, Gilbertson DT, et al. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. *Clin J Am Soc Nephrol*. 2009;4(Suppl 1):S5–11.
- Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. *Chest*. 2001;120:1883–1887.
- James MT, Quan H, Tonelli M, et al. CKD and risk of hospitalization and death with pneumonia. *Am J Kidney Dis*. 2009;54:24–32.
- Chung CJ, Huang CY, Tsai HB, et al. Sex differences in the development of malignancies among end-stage renal disease patients: a nationwide population-based follow-up study in Taiwan. *PLoS One*. 2012;7:e44675.
- Liu JH, Lin SY, Hsu CY, et al. The risk for chronic kidney disease in patients with heart diseases: a 7-year follow-up in a cohort study in Taiwan. *BMC Nephrol*. 2012;13:77.
- Agarwal R, Bunaye Z, Bekele DM, et al. Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease. *Am J Nephrol*. 2008;28:569–575.
- Hwang SJ, Lin MY, Chen HC, et al. Increased risk of mortality in the elderly population with late-stage chronic kidney disease: a cohort study in Taiwan. *Nephrol Dial Transplant*. 2008;23:3192–3198.
- Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. *Thorax*. 2004;59:960–965.
- Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. *Kidney Int*. 2006;70:1135–1141.
- Lim WH, Kireta S, Leedham E, et al. Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. *Kidney Int*. 2007;72:1138–1148.
- Anding K, Gross P, Rost JM, et al. The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. *Nephrol Dial Transplant*. 2003;18:2067–2073.
- Sester U, Sester M, Hauk M, et al. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. *Nephrol Dial Transplant*. 2000;15:1217–1223.
- Fernandez-Fresnedo G, Ramos MA, Gonzalez-Pardo MC, et al. B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. *Nephrol Dial Transplant*. 2000;15:502–510.
- Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. *Kidney Int*. 1998;54:236–244.
- Arnold FW, Ramirez JA, McDonald LC, et al. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. *Chest*. 2003;124:121–124.
- Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia. Assessment of severity criteria. *Am J Respir Crit Care Med*. 1998;158:1102–1108.
- Di Angelantonio E, Chowdhury R, Sarwar N, et al. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. *BMJ*. 2010;341:c4986.
- Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. *JAMA*. 2011;305:1119–1127.
- Kent BD, Eltayeb EE, Woodman A, et al. The impact of chronic obstructive pulmonary disease and smoking on mortality and kidney transplantation in end-stage kidney disease. *Am J Nephrol*. 2012;36:287–295.
- van Gestel YR, Chonchol M, Hoeks SE, et al. Association between chronic obstructive pulmonary disease and chronic kidney disease in vascular surgery patients. *Nephrol Dial Transplant*. 2009;24:2763–2767.
- Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. *Am J Respir Crit Care Med*. 1999;160:397–405.